Kim Yu-Kyung, Minn Dohsik, Chang Soon-Hee, Suh Jang-Soo
Department of Clinical Pathology, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Department of Diagnostic Immunology, Seegene Medical Foundation, Seoul 05548, Korea.
Vaccines (Basel). 2022 Jan 26;10(2):193. doi: 10.3390/vaccines10020193.
Coronavirus disease 2019 (COVID-19) vaccination began for healthcare workers in South Korea at the end of February 2021. This study investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses after various COVID-19 vaccinations in healthcare workers. Blood specimens of 497 vaccinated healthcare workers were collected. Inoculated vaccines were ChAdOx1 (AstraZeneca/Oxford), BNT162b2 (Pfizer/BioNTech), JNJ-78436735 (Janssen), and mRNA-1273 (Moderna). Each specimen was tested for antibodies against SARS-CoV-2 using Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics), SARS-CoV-2 IgG II Quant assay (Abbott), and R-FIND SARS-CoV-2 Neutralizing Antibody kit (SG medical Inc.). A questionnaire was used to investigate adverse events related to vaccination. We found that 99.5% of the subjects showed a 96-100% positive rate in all three antibody assays, regardless of the vaccine type. The antibody-positive rate of completed vaccination groups reached 96-100%, and antibody quantities significantly increased 2 weeks after vaccination. The antibody values measured approximately 3 months after BNT162b2 inoculation significantly correlated with adverse events.
2021年2月底，韩国开始为医护人员接种2019冠状病毒病（COVID-19）疫苗。本研究调查了医护人员接种各种COVID-19疫苗后严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体反应。收集了497名接种疫苗的医护人员的血样。接种的疫苗有ChAdOx1（阿斯利康/牛津）、BNT162b2（辉瑞/生物科技）、JNJ-78436735（杨森）和mRNA-1273（莫德纳）。使用罗氏诊断公司的Elecsys Anti-SARS-CoV-2 S检测法、雅培公司的SARS-CoV-2 IgG II Quant检测法和SG medical Inc.公司的R-FIND SARS-CoV-2中和抗体试剂盒对每个样本进行SARS-CoV-2抗体检测。通过问卷调查来调查与疫苗接种相关的不良事件。我们发现，无论疫苗类型如何，99.5%的受试者在所有三种抗体检测中的阳性率均达到96-100%。完成接种组的抗体阳性率达到96-100%，接种后2周抗体量显著增加。接种BNT162b2约3个月后测得的抗体值与不良事件显著相关。
